Register now to join the National Parkinson Foundation on Thursday, February 26 at 1:00 p.m. ET for a special webinar discussing how arthritis, diabetes, the common cold and other ailments affect your Parkinson's disease.
The U.S. Food and Drug Administration (FDA) has approved DUOPA™, developed by AbbVie Inc., as a treatment for people with advanced Parkinson's disease. DUOPA™ is a new approach to the delivery of carbidopa and levodopa for the treatment of the motor symptoms of Parkinson's disease; it is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine.
Take action for people with Parkinson’s! Tell your Representative to sponsor HR 292, which would create a data collection system for Parkinson’s and other neurological diseases.
Impax Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease.